secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001193125-25-108726
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom Q1 net revenue $28.5M, net loss $94.3M; cuts costs, exec changes, targets 2026 profit
--------------------------------------------------------------------------------

- Net revenue $28.5M (up from $1.9M YoY); net loss $94.3M ($77.1M non-GAAP adjusted).
- Over 390k VOQUEZNA prescriptions filled; ~127k in Q1, up ~8% sequentially despite seasonal headwinds.
- Cost reduction: cut 2025 opex by $60-70M, reduce headcount ~6%, pause EoE trial, target Q4 spend <$55M.
- CEO restructuring: new SVP Sales from Intra-Cellular; COO, CCO, CFO exit; Ted Schroeder on Board.
- Citizen Petition filed Dec 2024 for 10-year NCE exclusivity; FDA response due within 180 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312525108726/0001193125-25-108726-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312525108726/d847727d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-108726

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer